Liraglutide Market Report 2026

Liraglutide Market Overview

• Liraglutide market size has reached to $6.88 billion in 2025 • Expected to grow to $10.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Impact Of Diabetic Population Growth On The Liraglutide Market • Market Trend: Expansion Of Generic GLP-1 Products In The Liraglutide Market • North America was the largest region and fastest growing region.

What Is Covered Under Liraglutide Market?

Liraglutide is a GLP-1 receptor agonist used to manage type 2 diabetes and obesity. It helps lower blood sugar levels and promotes weight loss by mimicking the incretin hormone GLP-1. Administered via subcutaneous injection, it enhances insulin secretion and reduces appetite. Liraglutide is marketed under the brand names Victoza for diabetes and Saxenda for obesity. The main liraglutide brands are victoza and saxenda. Victoza is a brand name for liraglutide, a medication used to treat type 2 diabetes. It can be distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacies, and it is used for diabetes treatment and weight management. It is used by various end-users, including hospitals, clinics, and home care settings.

What Is The Liraglutide Market Growth Forecast?

The liraglutide market size is expected to see strong growth in the next few years. It will grow to $10.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to growing global obesity burden, increasing preference for weight-centric diabetes treatments, expansion of metabolic disorder screening programs, rising patient demand for effective appetite-suppressing therapies, continued innovation and awareness in glp-1 based treatments. Major trends in the forecast period include strong adoption of liraglutide in type 2 diabetes management, rising use of liraglutide for medical weight management, growing acceptance of injectable glp-1 therapies, expansion of long-term metabolic disease management programs, increasing focus on dual benefits of glycemic control and weight loss.

Global Liraglutide Market Segmentation

1) By Brands: Victoza, Saxenda 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies 3) By Type Of Application: Diabetes Treatment, Weight Management 4) By End-Users: Hospitals And Clinics, Homecare Settings Subsegments: 1) By Victoza: Type 2 Diabetes Treatment Or Weight Management 2) By Saxenda: Weight Loss Treatment Or Obesity Management

What Is The Driver Of The Liraglutide Market?

The increasing diabetic population is expected to propel the growth of the liraglutide market going forward. Diabetes is a chronic condition where the body cannot properly regulate blood sugar levels, either due to insufficient insulin production or ineffective insulin use. The incidence of diabetes is increasing due to factors such as sedentary lifestyles, unhealthy diets, and rising obesity rates worldwide. Diabetes drugs such as liraglutide help by mimicking the action of the hormone GLP-1, which enhances insulin secretion, lowers blood sugar levels, and promotes weight loss, thereby aiding in the management of type 2 diabetes.For instance, in March 2024, according to a report by the Government of the United Kingdom, a UK-based information website, In March 2023, the proportion of people with type 1 diabetes in England receiving all 8 care processes at GP practices involved in the NDA increased to 43.8%, compared to 35.2% the year before. Therefore, the increasing diabetic population is driving the growth of the liraglutide industry.

Key Players In The Global Liraglutide Market

Major companies operating in the liraglutide market are Novo Nordisk A/S

Global Liraglutide Market Trends and Insights

Major companies operating in the liraglutide market are developing novel products, such as generic GLP-1, to expand treatment options and address market demand for more affordable alternatives. Generic GLP-1 refers to versions of GLP-1 receptor agonists that are produced after the expiration of patent protection on the original branded medications, offering cost-effective alternatives for treating conditions like type 2 diabetes and obesity. For instance, in June 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, introduced the first generic GLP-1, similar to Victoza, in the U.S. market, meeting the rising demand for these therapies. Liraglutide injections are prescribed to enhance blood sugar management in adults and children aged 10 and above with type 2 diabetes and to lower the risk of cardiovascular incidents in adults with type 2 diabetes and existing cardiovascular conditions.

What Are Latest Mergers And Acquisitions In The Liraglutide Market?

In October 2023, Biocon Limited, an India-based biopharmaceutical company, partnered with Juno Pharmaceuticals to commercialize its vertically integrated, complex formulation, Liraglutide. Under the terms of this partnership agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide and, thereafter, for the manufacture and supply of the product in the Canadian market. Juno Pharmaceuticals is a Canada-based pharmaceutical company that focuses on bringing complex and high-value generic and biosimilar products to the market.

Regional Insights

North America was the largest region in the liraglutide market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Liraglutide Market?

The liraglutide market consists of sales of insulin products, weight management supplements, nutritional supplements, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Liraglutide Market Report 2026?

The liraglutide market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.